EUVIMEDEUVIMED entdecken
Crossref

2496-P: Hepatocyte-Specific Estrogen Receptor Alpha Knockdown Exacerbates HFD-Induced MASLD

FELIPE N.D. CAMARGO, LETICIA F. AMARO, ANA L. DIAS MACIEL, ANNE R. MELO SANTOS, ALESSANDRA GONCALVES DA CRUZ, JESSICA D.M. DOS SANTOS, SANDRO L. MATOS, FELIPE SUCUPIRA, JORGE F.A. MODEL, JOAO PAULO CAMPOREZ

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-2496-p ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von FELIPE N.D. CAMARGO und 9 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) exhibits distinct sexual dimorphism, with premenopausal women displaying significant protection compared to men. This study investigated the impact of hepatocyte-specific Estrogen Receptor Alpha (ERα) knockdown on MASLD development.

Methods

Female C57BL/6J mice were treated with AAV8-TBG-GFP-mESR1-shRNAmir to knockdown ERα (AAV) or Vehicle (V) and fed a Regular Chow (RC) or High-Fat Diet (HFD) for 9 weeks. Statistical analyses: Two-way ANOVA followed by Fisher’s LSD test (p<0.05).

Results

HFD-AAV presented ~49% and ~59% lower liver ERα vs.HFD-V and RC-AAV, respectively. RC-AAV showed ~20% lower liver ERα vs. RC-V. HFD-AAV exhibited ~43% lower Esr1 mRNA expression vs. HFD-V, while RC-AAV exhibited a ~70% reduction vs. RC-V. Compared to their respective RC controls, HFD-V and HFD-AAV showed higher final body weight (~31%; ~30%), body fat (~116%; ~119%), and lean mass (~21%; ~24%). HFD-V and HFD-AAV displayed increased glucose intolerance (~52%; ~56%) vs. RC controls. AUC of insulinemia during oGTT did not differ. However, HFD-V and HFD-AAV had higher fasting plasma glucose (~20%; ~23%), lower fasting plasma insulin (~11%; ~6%) and HOMA-β (~33%; ~52%) vs. RC controls. HFD-AAV showed increased fasting plasma glucose (~15%) and HOMA-IR (~22%) vs. HFD-V. Insulin-stimulated hepatic levels of p-AKT2/Total AKT, plasma triglycerides and hepatic cholesterol did not differ between groups. HFD-V and HFD-AAV displayed increased plasma cholesterol (~10%; ~17%) vs. RC controls. Hepatic triglycerides and ORO area were ~39% and ~77%, respectively, higher in HFD-AAV vs. HFD-V. Plasma ALT and AST levels increased by ~66% and ~15%, respectively, while hepatic Tgfb mRNA expression increased ~200% in HFD-AAV vs. HFD-V.

Conclusion

Hepatocyte-specific ERα knockdown worsens HFD-induced hepatic steatosis, liver injury, and glucose metabolism. These findings underscore the critical protective role of hepatic ERα signaling against MASLD progression in females. Disclosure F.N. Camargo: None. L.F. Amaro: None. A.L. Dias Maciel: None. A.R. Melo Santos: None. A. Goncalves da Cruz: None. J.D. dos Santos: None. S.L. Matos: None. F. Sucupira: None. J.F. Model: None. J. Camporez: None. Funding Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP); Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq); Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES).

Zitieren

APA

CAMARGO, F. N., AMARO, L. F., MACIEL, A. L. D., SANTOS, A. R. M., CRUZ, A. G. D., SANTOS, J. D. D., MATOS, S. L., SUCUPIRA, F., MODEL, J. F., & CAMPOREZ, J. P. (2026). 2496-P: Hepatocyte-Specific Estrogen Receptor Alpha Knockdown Exacerbates HFD-Induced MASLD. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-2496-p

Vancouver

CAMARGO FN, AMARO LF, MACIEL ALD, SANTOS ARM, CRUZ AGD, SANTOS JDD, et al. 2496-P: Hepatocyte-Specific Estrogen Receptor Alpha Knockdown Exacerbates HFD-Induced MASLD. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-2496-p

BibTeX
@article{CAMARGO2026,
  author = {CAMARGO, FELIPE N.D. and AMARO, LETICIA F. and MACIEL, ANA L. DIAS and SANTOS, ANNE R. MELO and CRUZ, ALESSANDRA GONCALVES DA and SANTOS, JESSICA D.M. DOS and MATOS, SANDRO L. and SUCUPIRA, FELIPE and MODEL, JORGE F.A. and CAMPOREZ, JOAO PAULO},
  title = {2496-P: Hepatocyte-Specific Estrogen Receptor Alpha Knockdown Exacerbates HFD-Induced MASLD},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-2496-p}
}
Kostenlos starten →